CN103249424B - 用于治疗和预防病毒感染的新型环孢菌素衍生物 - Google Patents

用于治疗和预防病毒感染的新型环孢菌素衍生物 Download PDF

Info

Publication number
CN103249424B
CN103249424B CN201180058384.7A CN201180058384A CN103249424B CN 103249424 B CN103249424 B CN 103249424B CN 201180058384 A CN201180058384 A CN 201180058384A CN 103249424 B CN103249424 B CN 103249424B
Authority
CN
China
Prior art keywords
alkyl
groups
halogen
phenyl
different
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201180058384.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN103249424A (zh
Inventor
苏壮
龙正宇
黄震年
杨遂周
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hebei Kunxiang Jishi Pharmaceutical Co Ltd
Original Assignee
Hebei Kunxiang Jishi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hebei Kunxiang Jishi Pharmaceutical Co Ltd filed Critical Hebei Kunxiang Jishi Pharmaceutical Co Ltd
Publication of CN103249424A publication Critical patent/CN103249424A/zh
Application granted granted Critical
Publication of CN103249424B publication Critical patent/CN103249424B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64Cyclic peptides containing only normal peptide links
    • C07K7/645Cyclosporins; Related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13Cyclosporins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • AIDS & HIV (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN201180058384.7A 2010-12-03 2011-12-05 用于治疗和预防病毒感染的新型环孢菌素衍生物 Active CN103249424B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41932610P 2010-12-03 2010-12-03
US61/419,326 2010-12-03
PCT/US2011/063295 WO2012075494A1 (en) 2010-12-03 2011-12-05 Novel cyclosporin derivatives for the treatment and prevention of a viral infection

Publications (2)

Publication Number Publication Date
CN103249424A CN103249424A (zh) 2013-08-14
CN103249424B true CN103249424B (zh) 2016-08-10

Family

ID=46172312

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201180058384.7A Active CN103249424B (zh) 2010-12-03 2011-12-05 用于治疗和预防病毒感染的新型环孢菌素衍生物

Country Status (13)

Country Link
EP (1) EP2646043B1 (enExample)
JP (1) JP6093307B2 (enExample)
CN (1) CN103249424B (enExample)
AU (1) AU2011336266B2 (enExample)
BR (1) BR112013015771A2 (enExample)
CA (1) CA2819608C (enExample)
DK (1) DK2646043T3 (enExample)
ES (1) ES2625502T3 (enExample)
MX (1) MX350746B (enExample)
PT (1) PT2646043T (enExample)
RU (1) RU2601742C2 (enExample)
WO (1) WO2012075494A1 (enExample)
ZA (1) ZA201303610B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103153329A (zh) 2010-07-16 2013-06-12 美国科技环球有限公司 新颖的环孢霉素a衍生物在病毒感染的治疗和预防中的应用
CN103153330B (zh) 2010-08-12 2017-08-18 美国科技环球有限公司 新的环孢霉素衍生物在病毒感染的治疗和预防中的应用
CA2814192A1 (en) 2010-10-12 2012-04-19 Allergan, Inc. Cyclosporin analogs
JP5805773B2 (ja) 2010-10-12 2015-11-10 アラーガン、インコーポレイテッドAllergan,Incorporated シクロスポリンアナログ
US9890198B2 (en) 2010-12-03 2018-02-13 S&T Global Inc. Cyclosporin derivatives and uses thereof
US9266927B2 (en) 2012-06-01 2016-02-23 Allergan, Inc. Cyclosporin A analogs
WO2014049540A2 (en) * 2012-09-29 2014-04-03 Novartis Ag Cyclic peptides and use as medicines
CN105960246A (zh) * 2013-03-15 2016-09-21 美国科技环球有限公司 新型环孢菌素衍生物及其用途
US9914755B2 (en) 2015-01-08 2018-03-13 Allergan, Inc. Cyclosporin derivatives wherein the MeBmt sidechain has been cyclized
CN109476705B (zh) * 2016-05-17 2024-02-27 美国科技环球有限公司 新型环孢菌素衍生物及其用途
EP3914655B1 (en) 2019-01-24 2025-04-23 Agfa Nv Radiation curable inkjet inks for interior decoration
EP3686252A1 (en) 2019-01-24 2020-07-29 Agfa-Gevaert Nv Radiation curable inkjet ink for manufacturing printed circuit boards
CA3128410A1 (en) * 2019-10-11 2021-04-15 Waterstone Pharmaceuticals (Wuhan) Co., Ltd. Ws-635 uses thereof in medicine
WO2021209003A1 (en) 2020-04-15 2021-10-21 Farsight Medical Technology (Shanghai) Co., Ltd. Prevention and treatment of organ injuries
CN112154151B (zh) * 2020-06-04 2025-04-29 中美华世通生物医药科技(武汉)股份有限公司 治疗或预防冠状病毒科感染

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103153330A (zh) * 2010-08-12 2013-06-12 美国科技环球有限公司 新的环孢霉素衍生物在病毒感染的治疗和预防中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0194972B1 (en) * 1985-03-11 1992-07-29 Sandoz Ag Novel cyclosporins
HUP9900405A3 (en) * 1995-07-17 2001-04-28 Scynexis Inc Durham Cyclosporin derivatives with anti-hiv effect
US7511013B2 (en) * 2004-09-29 2009-03-31 Amr Technology, Inc. Cyclosporin analogues and their pharmaceutical uses
US7196161B2 (en) * 2004-10-01 2007-03-27 Scynexis Inc. 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis C infection
CN101068829B (zh) * 2004-10-01 2012-05-30 西尼克斯公司 用于治疗和预防丙型肝炎病毒感染的3-醚和3-硫醚取代的环孢菌素衍生物
PL1802650T3 (pl) * 2004-10-01 2012-04-30 Scynexis Inc 3-Etero i 3-tioetero podstawione pochodne cyklosporyny do leczenia i zapobiegania zakażeniu wirusem zapalenia wątroby typu C
MX2011007195A (es) * 2009-01-07 2013-07-12 Scynexis Inc Derivado de ciclosporina para el uso en el tratamiento de infección de virus de hepatitis c (vhc) y virus de inmunodeficiencia humana (vih).
CA2751210C (en) * 2009-01-30 2015-04-21 Enanta Pharmaceuticals, Inc. Cyclosporin analogues for preventing or treating hepatitis c infection

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103153330A (zh) * 2010-08-12 2013-06-12 美国科技环球有限公司 新的环孢霉素衍生物在病毒感染的治疗和预防中的应用

Also Published As

Publication number Publication date
DK2646043T3 (da) 2017-05-22
RU2013130256A (ru) 2015-01-10
MX350746B (es) 2017-09-14
CA2819608A1 (en) 2012-06-07
CA2819608C (en) 2020-03-31
RU2601742C2 (ru) 2016-11-10
EP2646043A4 (en) 2014-05-28
JP6093307B2 (ja) 2017-03-08
AU2011336266B2 (en) 2017-04-06
EP2646043B1 (en) 2017-02-15
JP2014500265A (ja) 2014-01-09
BR112013015771A2 (pt) 2018-11-06
ZA201303610B (en) 2014-07-30
AU2011336266A1 (en) 2013-06-27
ES2625502T3 (es) 2017-07-19
EP2646043A1 (en) 2013-10-09
PT2646043T (pt) 2017-05-09
MX2013006254A (es) 2013-10-30
CN103249424A (zh) 2013-08-14
WO2012075494A1 (en) 2012-06-07

Similar Documents

Publication Publication Date Title
CN103249424B (zh) 用于治疗和预防病毒感染的新型环孢菌素衍生物
JP7637421B2 (ja) 新規シクロスポリン誘導体及びその使用
CN103153330B (zh) 新的环孢霉素衍生物在病毒感染的治疗和预防中的应用
US9217015B2 (en) Cyclosporin derivatives for the treatment and prevention of a viral infection
CN105960246A (zh) 新型环孢菌素衍生物及其用途
US10647747B2 (en) Cyclosporin derivatives and uses thereof
JP2013513595A (ja) 新規環状ペプチド
JP2013516424A (ja) シクロスポリン類似体
HK1201181A1 (en) Novel cyclosporin derivatives for the treatment and prevention of viral infections
HK1188134A (en) Novel cyclosporin derivatives for the treatment and prevention of a viral infection
HK1188134B (en) Novel cyclosporin derivatives for the treatment and prevention of a viral infection
HK40005642B (zh) 新型环孢菌素衍生物及其用途
HK40005642A (en) Novel cyclosporin derivatives and uses thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1188134

Country of ref document: HK

ASS Succession or assignment of patent right

Owner name: HEBEI AEGIS BIOPHARMACEUTICAL CO., LTD.

Free format text: FORMER OWNER: S + T GLOBAL INC.

Effective date: 20140903

C41 Transfer of patent application or patent right or utility model
COR Change of bibliographic data

Free format text: CORRECT: ADDRESS; TO: 052165 SHIJIAZHUANG, HEBEI PROVINCE

TA01 Transfer of patent application right

Effective date of registration: 20140903

Address after: 052165 No. 136, the Yellow River Avenue, Shijiazhuang, Hebei 1510

Applicant after: HEBEI KUNXIANG JISHI PHARMACEUTICAL CO., LTD.

Address before: Woburn, Massachusetts

Applicant before: S&T Global, Inc.

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1188134

Country of ref document: HK